News & Updates
Automated regulatory and science updates gathered for each research compound.
Daily Briefing — 13 Updates Today
Thursday, October 15, 2026
The biggest story today is the growing regulatory split between anti-doping rules and U.S. compounding policy: WADA’s 2027 list maintains strict restrictions on several substances, while FDA advisory recommendations could eventually make a few peptides more accessible through compounding.
WADA’s 2027 update places non-approved substances under its S0 category, affecting items in today’s reports such as Melanotan II, PNC-27, PEG-MGF, oxytocin, Ovagen and NAD+. Separately, hexarelin and ipamorelin remain prohibited under the 2026 list, and BPC-157 remains prohibited under S0 while its compounding status faces continued FDA review. These updates concern athletic eligibility; they do not establish a substance’s safety or effectiveness.
On the compounding front, FDA advisory committees have recommended adding MOTS-c and KPV to the 503A bulk list, while GHK-Cu was among six peptides supported for eased regulation. These are recommendations, not final approvals, and safety and efficacy questions remain. WADA, meanwhile, says GLP-1 drugs such as tirzepatide remain off the 2027 prohibited list as it conducts further study.
Latest News
Ipamorelin: Status Update
Updated notes: Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use.
Updated notes: Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use. Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use.
NAD+: Status Update
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication. NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Cerebrolysin: Status Update
Updated notes: Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States.
Updated notes: Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States. Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States.
GHRP-2: Status Update
Clinical trial phase changed from "phase_3_complete" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies.
Clinical trial phase changed from "phase_3_complete" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies. GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies.
Selank: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Selank is approved for use in Russia but remains an unapproved research compound in the United States.
Clinical trial phase changed from "research_only" to "preclinical". Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Selank is approved for use in Russia but remains an unapproved research compound in the United States. Selank is approved for use in Russia but remains an unapproved research compound in the United States.
Ipamorelin: Status Update
Updated notes: Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use.
Updated notes: Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use. Ipamorelin is an investigational growth hormone secretagogue that has reached Phase 2 clinical testing but is not approved by the FDA for human use.
NAD+: Status Update
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication. NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Cerebrolysin: Status Update
Updated notes: Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States.
Updated notes: Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States. Cerebrolysin is approved for use in several international markets for neurological conditions but has not received FDA approval in the United States.
GHRP-2: Status Update
Clinical trial phase changed from "phase_3_complete" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies.
Clinical trial phase changed from "phase_3_complete" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies. GHRP-2 (Pralmorelin) is not FDA-approved and is classified as a research chemical, with its regulatory status restricted under FDA compounding policies.
Selank: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Selank is approved for use in Russia but remains an unapproved research compound in the United States.
Clinical trial phase changed from "research_only" to "preclinical". Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Selank is approved for use in Russia but remains an unapproved research compound in the United States. Selank is approved for use in Russia but remains an unapproved research compound in the United States.
Kisspeptin-10: Status Update
Updated notes: Kisspeptin-10 has no marketing authorization from the FDA, EMA, or MHRA. There are no large-scale human trials, and it remains classified as an investigational research chemical.
Updated notes: Kisspeptin-10 has no marketing authorization from the FDA, EMA, or MHRA. There are no large-scale human trials, and it remains classified as an investigational research chemical. Kisspeptin-10 has no marketing authorization from the FDA, EMA, or MHRA. There are no large-scale human trials, and it remains classified as an investigational research chemical.
Oxytocin: Status Update
Updated notes: Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, though it is also studied for various psychiatric and social indications.
Updated notes: Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, though it is also studied for various psychiatric and social indications. Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, though it is also studied for various psychiatric and social indications.
Retatrutide: Status Update
Updated notes: Retatrutide is currently in Phase 3 clinical trials for obesity and type 2 diabetes; it has not received FDA approval for any use.
Updated notes: Retatrutide is currently in Phase 3 clinical trials for obesity and type 2 diabetes; it has not received FDA approval for any use. Retatrutide is currently in Phase 3 clinical trials for obesity and type 2 diabetes; it has not received FDA approval for any use.
ARA-290: Status Update
Updated notes: ARA-290 (cibinetide) has reached phase 2 clinical trials but does not currently hold FDA approval for any medical use.
Updated notes: ARA-290 (cibinetide) has reached phase 2 clinical trials but does not currently hold FDA approval for any medical use. ARA-290 (cibinetide) has reached phase 2 clinical trials but does not currently hold FDA approval for any medical use.
BPC-157: Status Update
Updated notes: BPC-157 is not FDA-approved; while some small human reports exist, it lacks the large-scale clinical evidence required for regulatory approval.
Updated notes: BPC-157 is not FDA-approved; while some small human reports exist, it lacks the large-scale clinical evidence required for regulatory approval. BPC-157 is not FDA-approved; while some small human reports exist, it lacks the large-scale clinical evidence required for regulatory approval.
CJC-1295 No DAC: Status Update
Clinical trial phase changed from "research_only" to "phase_1". Updated notes: CJC-1295 has undergone early-phase human research but has not completed the Phase 3 clinical trial pathway required for FDA approval.
Clinical trial phase changed from "research_only" to "phase_1". Updated notes: CJC-1295 has undergone early-phase human research but has not completed the Phase 3 clinical trial pathway required for FDA approval. CJC-1295 has undergone early-phase human research but has not completed the Phase 3 clinical trial pathway required for FDA approval.
SS-31: Status Update
Updated notes: While some sources report accelerated approval for Barth syndrome, the FDA has explicitly classified SS-31 (Elamipretide) as an unapproved new drug in 2026.
Updated notes: While some sources report accelerated approval for Barth syndrome, the FDA has explicitly classified SS-31 (Elamipretide) as an unapproved new drug in 2026. While some sources report accelerated approval for Barth syndrome, the FDA has explicitly classified SS-31 (Elamipretide) as an unapproved new drug in 2026.
GHRP-6: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: GHRP-6 has no approval as a medicine from the FDA or other major regulatory bodies and is strictly sold for in vitro laboratory research purposes.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: GHRP-6 has no approval as a medicine from the FDA or other major regulatory bodies and is strictly sold for in vitro laboratory research purposes. GHRP-6 has no approval as a medicine from the FDA or other major regulatory bodies and is strictly sold for in vitro laboratory research purposes.
TB-500: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: TB-500 (Thymosin beta-4) is not FDA-approved and is currently under review for compounding status; it is generally restricted to research use.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: TB-500 (Thymosin beta-4) is not FDA-approved and is currently under review for compounding status; it is generally restricted to research use. TB-500 (Thymosin beta-4) is not FDA-approved and is currently under review for compounding status; it is generally restricted to research use.
CJC-1295: Status Update
Updated notes: CJC-1295 has undergone early-phase human research but has not completed the phase 3 pathway required for FDA approval and is subject to FDA safety concerns regarding impurities.
Updated notes: CJC-1295 has undergone early-phase human research but has not completed the phase 3 pathway required for FDA approval and is subject to FDA safety concerns regarding impurities. CJC-1295 has undergone early-phase human research but has not completed the phase 3 pathway required for FDA approval and is subject to FDA safety concerns regarding impurities.
Glutathione: Status Update
Updated notes: While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for human use and was subject to an FDA warning in 2026 regarding its marketing.
Updated notes: While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for human use and was subject to an FDA warning in 2026 regarding its marketing. While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for human use and was subject to an FDA warning in 2026 regarding its marketing.
Ipamorelin / CJC-1295 No DAC: Status Update
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: This combination is an investigational stack; while individual components like Ipamorelin have reached Phase 2, the combination itself lacks FDA approval and is restricted to research use.
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: This combination is an investigational stack; while individual components like Ipamorelin have reached Phase 2, the combination itself lacks FDA approval and is restricted to research use. This combination is an investigational stack; while individual components like Ipamorelin have reached Phase 2, the combination itself lacks FDA approval and is restricted to research use.
Pinealon: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Pinealon is not FDA-approved for any indication and has no established human dose from clinical trials, with only limited historical studies conducted in Russia.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Pinealon is not FDA-approved for any indication and has no established human dose from clinical trials, with only limited historical studies conducted in Russia. Pinealon is not FDA-approved for any indication and has no established human dose from clinical trials, with only limited historical studies conducted in Russia.
PNC-27: Status Update
Updated notes: PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and has not entered human clinical trials or received FDA approval.
Updated notes: PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and has not entered human clinical trials or received FDA approval. PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and has not entered human clinical trials or received FDA approval.
Vesugen: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vesugen is an investigational peptide primarily studied in laboratory settings and lacks formal human clinical trial data or FDA approval.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vesugen is an investigational peptide primarily studied in laboratory settings and lacks formal human clinical trial data or FDA approval. Vesugen is an investigational peptide primarily studied in laboratory settings and lacks formal human clinical trial data or FDA approval.
Thymosin Beta-4 Full Fragment: Status Update
Clinical trial phase changed from "phase_2" to "phase_3". Updated notes: The full-length protein has reached Phase 3 clinical trials (e.g., for neurotrophic keratopathy), but it remains unapproved by the FDA.
Clinical trial phase changed from "phase_2" to "phase_3". Updated notes: The full-length protein has reached Phase 3 clinical trials (e.g., for neurotrophic keratopathy), but it remains unapproved by the FDA. The full-length protein has reached Phase 3 clinical trials (e.g., for neurotrophic keratopathy), but it remains unapproved by the FDA.
Cartalax: Status Update
Updated notes: There is no reliable clinical trial data available for Cartalax, and it is not approved by the FDA for any human use.
Updated notes: There is no reliable clinical trial data available for Cartalax, and it is not approved by the FDA for any human use. There is no reliable clinical trial data available for Cartalax, and it is not approved by the FDA for any human use.
Tesamorelin: Status Update
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
VIP: Status Update
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: Vasoactive Intestinal Peptide (VIP) is currently under investigation in various clinical trials for conditions like respiratory distress, but it has not received FDA approval.
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: Vasoactive Intestinal Peptide (VIP) is currently under investigation in various clinical trials for conditions like respiratory distress, but it has not received FDA approval. Vasoactive Intestinal Peptide (VIP) is currently under investigation in various clinical trials for conditions like respiratory distress, but it has not received FDA approval.
AOD-9604: Status Update
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: AOD-9604 is not FDA-approved and has been flagged by the FDA regarding potential safety risks and lack of sufficient clinical data.
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: AOD-9604 is not FDA-approved and has been flagged by the FDA regarding potential safety risks and lack of sufficient clinical data. AOD-9604 is not FDA-approved and has been flagged by the FDA regarding potential safety risks and lack of sufficient clinical data.
Hexarelin: Status Update
Clinical trial phase changed from "phase_2" to "phase_1". Updated notes: Hexarelin is a synthetic growth hormone secretagogue that has undergone limited early-phase human trials but remains a research-only compound without FDA approval.
Clinical trial phase changed from "phase_2" to "phase_1". Updated notes: Hexarelin is a synthetic growth hormone secretagogue that has undergone limited early-phase human trials but remains a research-only compound without FDA approval. Hexarelin is a synthetic growth hormone secretagogue that has undergone limited early-phase human trials but remains a research-only compound without FDA approval.
Follistatin 344: Status Update
Updated notes: Follistatin-344 is not FDA-approved and is primarily sold as a research chemical; while gene therapy versions are in early-stage clinical trials, the injectable peptide form has no completed clinical trials.
Updated notes: Follistatin-344 is not FDA-approved and is primarily sold as a research chemical; while gene therapy versions are in early-stage clinical trials, the injectable peptide form has no completed clinical trials. Follistatin-344 is not FDA-approved and is primarily sold as a research chemical; while gene therapy versions are in early-stage clinical trials, the injectable peptide form has no completed clinical trials.
Melanotan II: Status Update
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: Melanotan II is not FDA-approved and is currently not authorized for compounding following the withdrawal of its nominations. It is scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027.
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: Melanotan II is not FDA-approved and is currently not authorized for compounding following the withdrawal of its nominations. It is scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027. Melanotan II is not FDA-approved and is currently not authorized for compounding following the withdrawal of its nominations. It is scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027.
KPV: Status Update
Updated notes: KPV is not FDA-approved for any indication. While it was subject to a 2026 Pharmacy Compounding Advisory Committee (PCAC) vote regarding 503A status, the FDA has identified no human clinical studies evaluating it for its proposed uses.
Updated notes: KPV is not FDA-approved for any indication. While it was subject to a 2026 Pharmacy Compounding Advisory Committee (PCAC) vote regarding 503A status, the FDA has identified no human clinical studies evaluating it for its proposed uses. KPV is not FDA-approved for any indication. While it was subject to a 2026 Pharmacy Compounding Advisory Committee (PCAC) vote regarding 503A status, the FDA has identified no human clinical studies evaluating it for its proposed uses.
MOTS-c: Status Update
Updated notes: MOTS-c is not FDA-approved and lacks a registered IND pathway for human therapeutic use. While it has been the subject of an advisory committee vote regarding compounding, the FDA has identified no human safety studies for the peptide.
Updated notes: MOTS-c is not FDA-approved and lacks a registered IND pathway for human therapeutic use. While it has been the subject of an advisory committee vote regarding compounding, the FDA has identified no human safety studies for the peptide. MOTS-c is not FDA-approved and lacks a registered IND pathway for human therapeutic use. While it has been the subject of an advisory committee vote regarding compounding, the FDA has identified no human safety studies for the peptide.
LL-37: Status Update
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: LL-37 is not FDA-approved for human use. Although it has been studied in laboratory and preclinical settings for immune and wound-healing properties, there is no approved therapeutic product.
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: LL-37 is not FDA-approved for human use. Although it has been studied in laboratory and preclinical settings for immune and wound-healing properties, there is no approved therapeutic product. LL-37 is not FDA-approved for human use. Although it has been studied in laboratory and preclinical settings for immune and wound-healing properties, there is no approved therapeutic product.
DSIP: Status Update
Updated notes: Delta Sleep-Inducing Peptide (DSIP) remains in the research-only category with no active clinical development programs for FDA approval.
Updated notes: Delta Sleep-Inducing Peptide (DSIP) remains in the research-only category with no active clinical development programs for FDA approval. Delta Sleep-Inducing Peptide (DSIP) remains in the research-only category with no active clinical development programs for FDA approval.
GLOW: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GLOW is a research-chemical blend of GHK-Cu, BPC-157, and TB-500; no clinical trials have evaluated the safety or efficacy of this combination in humans.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GLOW is a research-chemical blend of GHK-Cu, BPC-157, and TB-500; no clinical trials have evaluated the safety or efficacy of this combination in humans. GLOW is a research-chemical blend of GHK-Cu, BPC-157, and TB-500; no clinical trials have evaluated the safety or efficacy of this combination in humans.
Melanotan I: Status Update
Updated notes: Melanotan I (afamelanotide) has undergone extensive clinical testing, including Phase 3 trials. While it is approved in some international jurisdictions (e.g., EU/Australia) for specific conditions, it is not FDA-approved for general use in the United States.
Updated notes: Melanotan I (afamelanotide) has undergone extensive clinical testing, including Phase 3 trials. While it is approved in some international jurisdictions (e.g., EU/Australia) for specific conditions, it is not FDA-approved for general use in the United States. Melanotan I (afamelanotide) has undergone extensive clinical testing, including Phase 3 trials. While it is approved in some international jurisdictions (e.g., EU/Australia) for specific conditions, it is not FDA-approved for general use in the United States.
PT-141: Status Update
Updated notes: Bremelanotide is FDA-approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Updated notes: Bremelanotide is FDA-approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is FDA-approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Thymosin Alpha-1: Status Update
Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Thymosin Alpha-1 is approved as a pharmaceutical (Zadaxin) in over 35 countries but has never received FDA approval in the United States and was recently rejected by the PCAC.
Regulatory status changed from "not_fda_approved" to "approved_international_only". Updated notes: Thymosin Alpha-1 is approved as a pharmaceutical (Zadaxin) in over 35 countries but has never received FDA approval in the United States and was recently rejected by the PCAC. Thymosin Alpha-1 is approved as a pharmaceutical (Zadaxin) in over 35 countries but has never received FDA approval in the United States and was recently rejected by the PCAC.
KLOW: Status Update
Updated notes: KLOW is a research-only compound and is not an FDA-approved therapeutic agent; there is no evidence of clinical trial progression for this specific designation.
Updated notes: KLOW is a research-only compound and is not an FDA-approved therapeutic agent; there is no evidence of clinical trial progression for this specific designation. KLOW is a research-only compound and is not an FDA-approved therapeutic agent; there is no evidence of clinical trial progression for this specific designation.
Dihexa: Status Update
Updated notes: Dihexa research is limited to preclinical studies; there are no published human clinical trials and it is not approved by the FDA.
Updated notes: Dihexa research is limited to preclinical studies; there are no published human clinical trials and it is not approved by the FDA. Dihexa research is limited to preclinical studies; there are no published human clinical trials and it is not approved by the FDA.
Tirzepatide: Status Update
Updated notes: Tirzepatide is FDA-approved for the treatment of type 2 diabetes and chronic weight management.
Updated notes: Tirzepatide is FDA-approved for the treatment of type 2 diabetes and chronic weight management. Tirzepatide is FDA-approved for the treatment of type 2 diabetes and chronic weight management.
IGF-1 LR3: Status Update
Updated notes: IGF-1 LR3 is classified as a research chemical with no active IND applications or large-scale human clinical trials, and it is not approved by the FDA for any therapeutic indication.
Updated notes: IGF-1 LR3 is classified as a research chemical with no active IND applications or large-scale human clinical trials, and it is not approved by the FDA for any therapeutic indication. IGF-1 LR3 is classified as a research chemical with no active IND applications or large-scale human clinical trials, and it is not approved by the FDA for any therapeutic indication.
Vilon: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vilon is considered an investigational compound with no registered human clinical trials and no FDA approval for therapeutic use.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vilon is considered an investigational compound with no registered human clinical trials and no FDA approval for therapeutic use. Vilon is considered an investigational compound with no registered human clinical trials and no FDA approval for therapeutic use.
Semaglutide: Status Update
Updated notes: Semaglutide is FDA-approved for type 2 diabetes and chronic weight management under brand names including Ozempic, Rybelsus, and Wegovy, with recent approvals for higher-dose formulations.
Updated notes: Semaglutide is FDA-approved for type 2 diabetes and chronic weight management under brand names including Ozempic, Rybelsus, and Wegovy, with recent approvals for higher-dose formulations. Semaglutide is FDA-approved for type 2 diabetes and chronic weight management under brand names including Ozempic, Rybelsus, and Wegovy, with recent approvals for higher-dose formulations.
Epithalon: Status Update
Updated notes: Epithalon is a synthetic peptide primarily studied for its potential anti-aging and telomerase-activating properties, but it lacks FDA approval for any human therapeutic use.
Updated notes: Epithalon is a synthetic peptide primarily studied for its potential anti-aging and telomerase-activating properties, but it lacks FDA approval for any human therapeutic use. Epithalon is a synthetic peptide primarily studied for its potential anti-aging and telomerase-activating properties, but it lacks FDA approval for any human therapeutic use.
Sermorelin: Status Update
Clinical trial phase changed from "research_only" to "phase_3_complete". Updated notes: Sermorelin is not currently FDA-approved for general use, though its API remains on Category 1 of the FDA's list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions.
Clinical trial phase changed from "research_only" to "phase_3_complete". Updated notes: Sermorelin is not currently FDA-approved for general use, though its API remains on Category 1 of the FDA's list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions. Sermorelin is not currently FDA-approved for general use, though its API remains on Category 1 of the FDA's list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions.
Ovagen: Status Update
Updated notes: Ovagen is a research-grade peptide with no registered human clinical trials or FDA-approved indications; its status remains strictly research-only.
Updated notes: Ovagen is a research-grade peptide with no registered human clinical trials or FDA-approved indications; its status remains strictly research-only. Ovagen is a research-grade peptide with no registered human clinical trials or FDA-approved indications; its status remains strictly research-only.
Cagrilintide: Status Update
Regulatory status changed from "phase_3_trial" to "not_fda_approved". Updated notes: Cagrilintide is currently in Phase 3 clinical trials as a monotherapy and in combination with semaglutide (CagriSema); it is not FDA-approved.
Regulatory status changed from "phase_3_trial" to "not_fda_approved". Updated notes: Cagrilintide is currently in Phase 3 clinical trials as a monotherapy and in combination with semaglutide (CagriSema); it is not FDA-approved. Cagrilintide is currently in Phase 3 clinical trials as a monotherapy and in combination with semaglutide (CagriSema); it is not FDA-approved.
Semax: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Semax is not FDA-approved; while it was recommended for the 503A bulks list by an advisory committee in July 2026, this is a non-binding recommendation and does not constitute FDA approval.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Semax is not FDA-approved; while it was recommended for the 503A bulks list by an advisory committee in July 2026, this is a non-binding recommendation and does not constitute FDA approval. Semax is not FDA-approved; while it was recommended for the 503A bulks list by an advisory committee in July 2026, this is a non-binding recommendation and does not constitute FDA approval.
MK-677: Status Update
Updated notes: MK-677 (ibutamoren) has reached Phase 3 clinical trials for various indications but has not received FDA approval for human use. It is widely recognized as a research compound and is prohibited in competitive sports.
Updated notes: MK-677 (ibutamoren) has reached Phase 3 clinical trials for various indications but has not received FDA approval for human use. It is widely recognized as a research compound and is prohibited in competitive sports. MK-677 (ibutamoren) has reached Phase 3 clinical trials for various indications but has not received FDA approval for human use. It is widely recognized as a research compound and is prohibited in competitive sports.
5-Amino-1MQ: Status Update
Updated notes: 5-Amino-1MQ is a research-only compound with no identified human clinical trials and no FDA-approved indications.
Updated notes: 5-Amino-1MQ is a research-only compound with no identified human clinical trials and no FDA-approved indications. 5-Amino-1MQ is a research-only compound with no identified human clinical trials and no FDA-approved indications.
PEG-MGF: Status Update
Updated notes: PEG-MGF is a research-use-only compound with no human clinical trials and no FDA approval; it is prohibited by WADA for use in competitive sports.
Updated notes: PEG-MGF is a research-use-only compound with no human clinical trials and no FDA approval; it is prohibited by WADA for use in competitive sports. PEG-MGF is a research-use-only compound with no human clinical trials and no FDA approval; it is prohibited by WADA for use in competitive sports.
Thymosin Beta-4 (Fragment): Status Update
Updated notes: Often marketed as TB-500, this fragment lacks dedicated human clinical trials and is not FDA-approved for any use.
Updated notes: Often marketed as TB-500, this fragment lacks dedicated human clinical trials and is not FDA-approved for any use. Often marketed as TB-500, this fragment lacks dedicated human clinical trials and is not FDA-approved for any use.
AICAR: Status Update
Updated notes: AICAR has been examined in phase 2 clinical trials for conditions like Type 2 Diabetes, but it remains a research-only compound without FDA approval.
Updated notes: AICAR has been examined in phase 2 clinical trials for conditions like Type 2 Diabetes, but it remains a research-only compound without FDA approval. AICAR has been examined in phase 2 clinical trials for conditions like Type 2 Diabetes, but it remains a research-only compound without FDA approval.
GHK-Cu: Status Update
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: GHK-Cu is approved for cosmetic and topical use globally, but it is not FDA-approved as an injectable drug and remains in the research-only category for systemic applications.
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: GHK-Cu is approved for cosmetic and topical use globally, but it is not FDA-approved as an injectable drug and remains in the research-only category for systemic applications. GHK-Cu is approved for cosmetic and topical use globally, but it is not FDA-approved as an injectable drug and remains in the research-only category for systemic applications.
SLU-PP-332: Status Update
Updated notes: SLU-PP-332 is a research tool compound with no human clinical trials registered or conducted as of September 2026.
Updated notes: SLU-PP-332 is a research tool compound with no human clinical trials registered or conducted as of September 2026. SLU-PP-332 is a research tool compound with no human clinical trials registered or conducted as of September 2026.
PEG-MGF: Status Update
Updated notes: PEG-MGF is not FDA-approved and has no published human clinical trials; it is currently classified as a research-use-only compound.
Updated notes: PEG-MGF is not FDA-approved and has no published human clinical trials; it is currently classified as a research-use-only compound. PEG-MGF is not FDA-approved and has no published human clinical trials; it is currently classified as a research-use-only compound.
PNC-27: Status Update
Updated notes: PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and cell-culture studies; it has no FDA approval or active human clinical trials.
Updated notes: PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and cell-culture studies; it has no FDA approval or active human clinical trials. PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and cell-culture studies; it has no FDA approval or active human clinical trials.
Selank: Status Update
Updated notes: Selank is a synthetic peptide developed internationally that is not FDA-approved for any medical use in the United States.
Updated notes: Selank is a synthetic peptide developed internationally that is not FDA-approved for any medical use in the United States. Selank is a synthetic peptide developed internationally that is not FDA-approved for any medical use in the United States.
Pinealon: Status Update
Updated notes: Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no registered clinical trials in the United States.
Updated notes: Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no registered clinical trials in the United States. Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no registered clinical trials in the United States.
Sermorelin: Status Update
Updated notes: Sermorelin is not FDA-approved for human use, though it remains on the FDA's Category 1 list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions.
Updated notes: Sermorelin is not FDA-approved for human use, though it remains on the FDA's Category 1 list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions. Sermorelin is not FDA-approved for human use, though it remains on the FDA's Category 1 list, allowing for compounding by accredited 503A pharmacies for patient-specific prescriptions.
Semax: Status Update
Updated notes: Semax is not FDA-approved; while a 2026 advisory committee recommended it for the 503A bulks list, this is a non-binding recommendation and does not constitute drug approval.
Updated notes: Semax is not FDA-approved; while a 2026 advisory committee recommended it for the 503A bulks list, this is a non-binding recommendation and does not constitute drug approval. Semax is not FDA-approved; while a 2026 advisory committee recommended it for the 503A bulks list, this is a non-binding recommendation and does not constitute drug approval.
Oxytocin: Status Update
Updated notes: Oxytocin is an FDA-approved medication used primarily for the induction of labor and the control of postpartum hemorrhage.
Updated notes: Oxytocin is an FDA-approved medication used primarily for the induction of labor and the control of postpartum hemorrhage. Oxytocin is an FDA-approved medication used primarily for the induction of labor and the control of postpartum hemorrhage.
SS-31: Status Update
Clinical trial phase changed from "approved" to "phase_3". Regulatory status changed from "fda_approved" to "not_fda_approved". Updated notes: Also known as elamipretide, it has undergone extensive clinical evaluation, including Phase 3 trials, but remains an investigational drug without final FDA approval.
Clinical trial phase changed from "approved" to "phase_3". Regulatory status changed from "fda_approved" to "not_fda_approved". Updated notes: Also known as elamipretide, it has undergone extensive clinical evaluation, including Phase 3 trials, but remains an investigational drug without final FDA approval. Also known as elamipretide, it has undergone extensive clinical evaluation, including Phase 3 trials, but remains an investigational drug without final FDA approval.
Melanotan II: Status Update
Clinical trial phase changed from "preclinical" to "phase_1". Updated notes: Melanotan II is not FDA-approved and is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected by February 2027. It has no completed Phase 2 or 3 efficacy trials and is not authorized for compounding.
Clinical trial phase changed from "preclinical" to "phase_1". Updated notes: Melanotan II is not FDA-approved and is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected by February 2027. It has no completed Phase 2 or 3 efficacy trials and is not authorized for compounding. Melanotan II is not FDA-approved and is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected by February 2027. It has no completed Phase 2 or 3 efficacy trials and is not authorized for compounding.
SLU-PP-332: Status Update
Updated notes: SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no sanctioned human clinical trials.
Updated notes: SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no sanctioned human clinical trials. SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no sanctioned human clinical trials.
Melanotan I: Status Update
Clinical trial phase changed from "preclinical" to "phase_3". Updated notes: Melanotan I (afamelanotide) is approved in international markets (e.g., EU) for specific indications, but it is not FDA-approved for general use in the United States.
Clinical trial phase changed from "preclinical" to "phase_3". Updated notes: Melanotan I (afamelanotide) is approved in international markets (e.g., EU) for specific indications, but it is not FDA-approved for general use in the United States. Melanotan I (afamelanotide) is approved in international markets (e.g., EU) for specific indications, but it is not FDA-approved for general use in the United States.
MK-677: Status Update
Updated notes: MK-677 (ibutamoren) is not FDA-approved and is currently listed as a Category 2 substance by the FDA due to identified safety risks.
Updated notes: MK-677 (ibutamoren) is not FDA-approved and is currently listed as a Category 2 substance by the FDA due to identified safety risks. MK-677 (ibutamoren) is not FDA-approved and is currently listed as a Category 2 substance by the FDA due to identified safety risks.
LL-37: Status Update
Clinical trial phase changed from "phase_3" to "phase_2". Updated notes: LL-37 is not FDA-approved; while a synthetic version (ropocamptide) has completed Phase IIb trials for wound healing, the research-grade peptide sold online lacks human clinical support.
Clinical trial phase changed from "phase_3" to "phase_2". Updated notes: LL-37 is not FDA-approved; while a synthetic version (ropocamptide) has completed Phase IIb trials for wound healing, the research-grade peptide sold online lacks human clinical support. LL-37 is not FDA-approved; while a synthetic version (ropocamptide) has completed Phase IIb trials for wound healing, the research-grade peptide sold online lacks human clinical support.
Kisspeptin-10: Status Update
Updated notes: Kisspeptin-10 is not FDA-approved and is currently classified by the FDA as a Category 2 substance, indicating significant safety risks.
Updated notes: Kisspeptin-10 is not FDA-approved and is currently classified by the FDA as a Category 2 substance, indicating significant safety risks. Kisspeptin-10 is not FDA-approved and is currently classified by the FDA as a Category 2 substance, indicating significant safety risks.
Semaglutide: Status Update
Updated notes: Semaglutide is FDA-approved under the brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing supplemental approvals for new dosage forms.
Updated notes: Semaglutide is FDA-approved under the brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing supplemental approvals for new dosage forms. Semaglutide is FDA-approved under the brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing supplemental approvals for new dosage forms.
KLOW: Status Update
Updated notes: KLOW is not an FDA-approved therapeutic agent and is classified as a research compound with no established clinical trial pathway for human use.
Updated notes: KLOW is not an FDA-approved therapeutic agent and is classified as a research compound with no established clinical trial pathway for human use. KLOW is not an FDA-approved therapeutic agent and is classified as a research compound with no established clinical trial pathway for human use.
Ipamorelin / CJC-1295 No DAC: Status Update
Clinical trial phase changed from "phase_2" to "research_only". Updated notes: This combination is not FDA-approved and has not undergone formal clinical trials as a stack; both individual components lack regulatory approval for human therapeutic use.
Clinical trial phase changed from "phase_2" to "research_only". Updated notes: This combination is not FDA-approved and has not undergone formal clinical trials as a stack; both individual components lack regulatory approval for human therapeutic use. This combination is not FDA-approved and has not undergone formal clinical trials as a stack; both individual components lack regulatory approval for human therapeutic use.
Ipamorelin: Status Update
Updated notes: Ipamorelin reached Phase 2 clinical trials for ileus but failed to meet endpoints and was never approved by the FDA; it is currently listed on the FDA's 503B Category 2 list.
Updated notes: Ipamorelin reached Phase 2 clinical trials for ileus but failed to meet endpoints and was never approved by the FDA; it is currently listed on the FDA's 503B Category 2 list. Ipamorelin reached Phase 2 clinical trials for ileus but failed to meet endpoints and was never approved by the FDA; it is currently listed on the FDA's 503B Category 2 list.
Hexarelin: Status Update
Updated notes: Hexarelin has undergone limited human clinical trials for endocrine testing but remains a research peptide without FDA approval for any therapeutic indication.
Updated notes: Hexarelin has undergone limited human clinical trials for endocrine testing but remains a research peptide without FDA approval for any therapeutic indication. Hexarelin has undergone limited human clinical trials for endocrine testing but remains a research peptide without FDA approval for any therapeutic indication.
MOTS-c: Status Update
Updated notes: MOTS-c is not FDA-approved and remains in the preclinical research stage with no active commercial sponsor pursuing human trials.
Updated notes: MOTS-c is not FDA-approved and remains in the preclinical research stage with no active commercial sponsor pursuing human trials. MOTS-c is not FDA-approved and remains in the preclinical research stage with no active commercial sponsor pursuing human trials.
Glutathione: Status Update
Updated notes: While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for systemic use and has been subject to FDA warnings regarding intravenous administration.
Updated notes: While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for systemic use and has been subject to FDA warnings regarding intravenous administration. While glutathione is a naturally occurring antioxidant, it is not FDA-approved as a therapeutic drug for systemic use and has been subject to FDA warnings regarding intravenous administration.
GLOW: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: GLOW is a market label for a research-chemical blend of BPC-157, TB-500, and GHK-Cu; no clinical trials have evaluated the safety or efficacy of this combination.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: GLOW is a market label for a research-chemical blend of BPC-157, TB-500, and GHK-Cu; no clinical trials have evaluated the safety or efficacy of this combination. GLOW is a market label for a research-chemical blend of BPC-157, TB-500, and GHK-Cu; no clinical trials have evaluated the safety or efficacy of this combination.
GHRP-6: Status Update
Updated notes: GHRP-6 is used exclusively as a pharmacological tool in laboratory research and has not been authorized for human clinical use by the FDA or other major health agencies.
Updated notes: GHRP-6 is used exclusively as a pharmacological tool in laboratory research and has not been authorized for human clinical use by the FDA or other major health agencies. GHRP-6 is used exclusively as a pharmacological tool in laboratory research and has not been authorized for human clinical use by the FDA or other major health agencies.
GHRP-2: Status Update
Clinical trial phase changed from "phase_2" to "phase_3_complete". Updated notes: GHRP-2 (Pralmorelin) is approved in Japan for use as a diagnostic test for growth hormone deficiency but has not received FDA approval for any therapeutic use.
Clinical trial phase changed from "phase_2" to "phase_3_complete". Updated notes: GHRP-2 (Pralmorelin) is approved in Japan for use as a diagnostic test for growth hormone deficiency but has not received FDA approval for any therapeutic use. GHRP-2 (Pralmorelin) is approved in Japan for use as a diagnostic test for growth hormone deficiency but has not received FDA approval for any therapeutic use.
GHK-Cu: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: While GHK-Cu is used in cosmetic and topical applications, it is not FDA-approved as an injectable drug and remains restricted to research-only use for that route.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: While GHK-Cu is used in cosmetic and topical applications, it is not FDA-approved as an injectable drug and remains restricted to research-only use for that route. While GHK-Cu is used in cosmetic and topical applications, it is not FDA-approved as an injectable drug and remains restricted to research-only use for that route.
Follistatin 344: Status Update
Updated notes: Follistatin 344 is not FDA-approved and is primarily investigated in preclinical research or as part of experimental gene therapy trials for muscular dystrophy.
Updated notes: Follistatin 344 is not FDA-approved and is primarily investigated in preclinical research or as part of experimental gene therapy trials for muscular dystrophy. Follistatin 344 is not FDA-approved and is primarily investigated in preclinical research or as part of experimental gene therapy trials for muscular dystrophy.
KPV: Status Update
Updated notes: KPV is not FDA-approved, though it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A Bulks List for wound healing and inflammatory conditions.
Updated notes: KPV is not FDA-approved, though it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A Bulks List for wound healing and inflammatory conditions. KPV is not FDA-approved, though it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A Bulks List for wound healing and inflammatory conditions.
IGF-1 LR3: Status Update
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: IGF-1 LR3 is a research-only analogue of IGF-1 and has not received FDA approval; the only FDA-approved IGF-1 product is mecasermin for specific pediatric deficiencies.
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: IGF-1 LR3 is a research-only analogue of IGF-1 and has not received FDA approval; the only FDA-approved IGF-1 product is mecasermin for specific pediatric deficiencies. IGF-1 LR3 is a research-only analogue of IGF-1 and has not received FDA approval; the only FDA-approved IGF-1 product is mecasermin for specific pediatric deficiencies.
Dihexa: Status Update
Updated notes: Dihexa is an investigational compound with evidence limited to preclinical studies; it is not FDA-approved and lacks human clinical trial data.
Updated notes: Dihexa is an investigational compound with evidence limited to preclinical studies; it is not FDA-approved and lacks human clinical trial data. Dihexa is an investigational compound with evidence limited to preclinical studies; it is not FDA-approved and lacks human clinical trial data.
DSIP: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Delta-sleep-inducing peptide (DSIP) is primarily studied in preclinical research and is not FDA-approved for any medical indication.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Delta-sleep-inducing peptide (DSIP) is primarily studied in preclinical research and is not FDA-approved for any medical indication. Delta-sleep-inducing peptide (DSIP) is primarily studied in preclinical research and is not FDA-approved for any medical indication.
Cerebrolysin: Status Update
Updated notes: Cerebrolysin is approved for use in several countries outside the United States for conditions like stroke and dementia, but it has not received FDA approval.
Updated notes: Cerebrolysin is approved for use in several countries outside the United States for conditions like stroke and dementia, but it has not received FDA approval. Cerebrolysin is approved for use in several countries outside the United States for conditions like stroke and dementia, but it has not received FDA approval.
Cagrilintide: Status Update
Updated notes: Cagrilintide is currently in Phase 3 clinical trials, both as a monotherapy and in combination with semaglutide (CagriSema). A New Drug Application for the combination was submitted to the FDA in December 2025, with a decision pending as of late 2026.
Updated notes: Cagrilintide is currently in Phase 3 clinical trials, both as a monotherapy and in combination with semaglutide (CagriSema). A New Drug Application for the combination was submitted to the FDA in December 2025, with a decision pending as of late 2026. Cagrilintide is currently in Phase 3 clinical trials, both as a monotherapy and in combination with semaglutide (CagriSema). A New Drug Application for the combination was submitted to the FDA in December 2025, with a decision pending as of late 2026.
CJC-1295 No DAC: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in laboratory research settings and lacks FDA approval for human therapeutic use.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in laboratory research settings and lacks FDA approval for human therapeutic use. CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in laboratory research settings and lacks FDA approval for human therapeutic use.
CJC-1295: Status Update
Updated notes: CJC-1295 has been studied in human trials, but the FDA has identified safety concerns regarding immunogenicity and impurities, and it is not approved for use.
Updated notes: CJC-1295 has been studied in human trials, but the FDA has identified safety concerns regarding immunogenicity and impurities, and it is not approved for use. CJC-1295 has been studied in human trials, but the FDA has identified safety concerns regarding immunogenicity and impurities, and it is not approved for use.
ARA-290: Status Update
Updated notes: Also known as cibinetide, this peptide has reached Phase 2 clinical trials for healing and recovery indications but lacks FDA approval.
Updated notes: Also known as cibinetide, this peptide has reached Phase 2 clinical trials for healing and recovery indications but lacks FDA approval. Also known as cibinetide, this peptide has reached Phase 2 clinical trials for healing and recovery indications but lacks FDA approval.
Epithalon: Status Update
Updated notes: Epithalon is primarily studied in preclinical models for its potential telomerase-activating and anti-aging properties, with no FDA-approved clinical applications.
Updated notes: Epithalon is primarily studied in preclinical models for its potential telomerase-activating and anti-aging properties, with no FDA-approved clinical applications. Epithalon is primarily studied in preclinical models for its potential telomerase-activating and anti-aging properties, with no FDA-approved clinical applications.
AOD-9604: Status Update
Updated notes: Although it has undergone multiple human clinical trials, including a Phase IIb study, it failed to achieve primary efficacy endpoints and is not FDA-approved.
Updated notes: Although it has undergone multiple human clinical trials, including a Phase IIb study, it failed to achieve primary efficacy endpoints and is not FDA-approved. Although it has undergone multiple human clinical trials, including a Phase IIb study, it failed to achieve primary efficacy endpoints and is not FDA-approved.
AICAR: Status Update
Updated notes: AICAR has been investigated in clinical trials for various conditions, including ischemia and metabolic disorders, but it is not FDA-approved for any human use.
Updated notes: AICAR has been investigated in clinical trials for various conditions, including ischemia and metabolic disorders, but it is not FDA-approved for any human use. AICAR has been investigated in clinical trials for various conditions, including ischemia and metabolic disorders, but it is not FDA-approved for any human use.
5-Amino-1MQ: Status Update
Updated notes: No human clinical trials have been identified for this compound, and it remains in the preclinical research stage.
Updated notes: No human clinical trials have been identified for this compound, and it remains in the preclinical research stage. No human clinical trials have been identified for this compound, and it remains in the preclinical research stage.
PT-141: Status Update
Updated notes: Bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women.
Updated notes: Bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women.
Vilon: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Vilon is not FDA-approved and lacks formal human clinical trials, existing solely as an investigational compound for research purposes.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Vilon is not FDA-approved and lacks formal human clinical trials, existing solely as an investigational compound for research purposes. Vilon is not FDA-approved and lacks formal human clinical trials, existing solely as an investigational compound for research purposes.
Cartalax: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Cartalax is a research peptide with no established clinical trial history or FDA approval for human use.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Cartalax is a research peptide with no established clinical trial history or FDA approval for human use. Cartalax is a research peptide with no established clinical trial history or FDA approval for human use.
Vesugen: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Vesugen is a bioregulator peptide that is not FDA-approved and is currently restricted to research-only status.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Vesugen is a bioregulator peptide that is not FDA-approved and is currently restricted to research-only status. Vesugen is a bioregulator peptide that is not FDA-approved and is currently restricted to research-only status.
BPC-157: Status Update
Updated notes: BPC-157 is widely studied in preclinical animal models, but there is limited published human efficacy evidence and no FDA-approved medical use.
Updated notes: BPC-157 is widely studied in preclinical animal models, but there is limited published human efficacy evidence and no FDA-approved medical use. BPC-157 is widely studied in preclinical animal models, but there is limited published human efficacy evidence and no FDA-approved medical use.
Ovagen: Status Update
Updated notes: Ovagen is a research-grade peptide with no established human clinical trial data or FDA-approved indications; it is strictly for research use only.
Updated notes: Ovagen is a research-grade peptide with no established human clinical trial data or FDA-approved indications; it is strictly for research use only. Ovagen is a research-grade peptide with no established human clinical trial data or FDA-approved indications; it is strictly for research use only.
VIP: Status Update
Updated notes: Vasoactive Intestinal Peptide (VIP) is primarily utilized in research settings and does not currently hold FDA approval for therapeutic use.
Updated notes: Vasoactive Intestinal Peptide (VIP) is primarily utilized in research settings and does not currently hold FDA approval for therapeutic use. Vasoactive Intestinal Peptide (VIP) is primarily utilized in research settings and does not currently hold FDA approval for therapeutic use.
NAD+: Status Update
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: NAD+ is currently being investigated in various clinical trials, including Phase 2 studies for metabolic and age-related conditions, but it does not hold FDA approval as a therapeutic drug.
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: NAD+ is currently being investigated in various clinical trials, including Phase 2 studies for metabolic and age-related conditions, but it does not hold FDA approval as a therapeutic drug. NAD+ is currently being investigated in various clinical trials, including Phase 2 studies for metabolic and age-related conditions, but it does not hold FDA approval as a therapeutic drug.
Tirzepatide: Status Update
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Thymosin Beta-4 Full Fragment: Status Update
Clinical trial phase changed from "phase_3" to "phase_2". Updated notes: Full-length Thymosin Beta-4 has undergone Phase 2 clinical trials for conditions like acute myocardial infarction, but it remains unapproved by the FDA.
Clinical trial phase changed from "phase_3" to "phase_2". Updated notes: Full-length Thymosin Beta-4 has undergone Phase 2 clinical trials for conditions like acute myocardial infarction, but it remains unapproved by the FDA. Full-length Thymosin Beta-4 has undergone Phase 2 clinical trials for conditions like acute myocardial infarction, but it remains unapproved by the FDA.
Retatrutide: Status Update
Regulatory status changed from "phase_3_trial" to "not_fda_approved". Updated notes: Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) for obesity and metabolic conditions, with potential FDA filings anticipated in 2027.
Regulatory status changed from "phase_3_trial" to "not_fda_approved". Updated notes: Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) for obesity and metabolic conditions, with potential FDA filings anticipated in 2027. Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) for obesity and metabolic conditions, with potential FDA filings anticipated in 2027.
Thymosin Beta-4 (Fragment): Status Update
Updated notes: TB-500 is a synthetic fragment that is not FDA-approved for human use and lacks dedicated human clinical trials, though it is often sold as a research chemical.
Updated notes: TB-500 is a synthetic fragment that is not FDA-approved for human use and lacks dedicated human clinical trials, though it is often sold as a research chemical. TB-500 is a synthetic fragment that is not FDA-approved for human use and lacks dedicated human clinical trials, though it is often sold as a research chemical.
Thymosin Alpha-1: Status Update
Clinical trial phase changed from "research_only" to "phase_3_complete". Updated notes: While approved as a pharmaceutical (Zadaxin) in over 35 countries, it has never received FDA approval in the United States and was explicitly recommended against by the PCAC in 2024.
Clinical trial phase changed from "research_only" to "phase_3_complete". Updated notes: While approved as a pharmaceutical (Zadaxin) in over 35 countries, it has never received FDA approval in the United States and was explicitly recommended against by the PCAC in 2024. While approved as a pharmaceutical (Zadaxin) in over 35 countries, it has never received FDA approval in the United States and was explicitly recommended against by the PCAC in 2024.
Tesamorelin: Status Update
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and subsequent formulations like EGRIFTA SV) for the treatment of HIV-associated lipodystrophy.
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and subsequent formulations like EGRIFTA SV) for the treatment of HIV-associated lipodystrophy. Tesamorelin is FDA-approved under the brand name EGRIFTA (and subsequent formulations like EGRIFTA SV) for the treatment of HIV-associated lipodystrophy.
TB-500: Status Update
Updated notes: TB-500 (Thymosin Beta-4) is not FDA-approved and is currently restricted to research use only.
Updated notes: TB-500 (Thymosin Beta-4) is not FDA-approved and is currently restricted to research use only. TB-500 (Thymosin Beta-4) is not FDA-approved and is currently restricted to research use only.
Ovagen: Status Update
Updated notes: Ovagen is not FDA-approved and lacks established clinical trial data for human therapeutic use, remaining categorized as a research-only compound.
Updated notes: Ovagen is not FDA-approved and lacks established clinical trial data for human therapeutic use, remaining categorized as a research-only compound. Ovagen is not FDA-approved and lacks established clinical trial data for human therapeutic use, remaining categorized as a research-only compound.
NAD+: Status Update
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: NAD+ is not FDA-approved for therapeutic use in humans and is primarily sold as a research chemical or dietary supplement ingredient, lacking formal clinical trial approval for medical indications.
Clinical trial phase changed from "phase_2" to "preclinical". Updated notes: NAD+ is not FDA-approved for therapeutic use in humans and is primarily sold as a research chemical or dietary supplement ingredient, lacking formal clinical trial approval for medical indications. NAD+ is not FDA-approved for therapeutic use in humans and is primarily sold as a research chemical or dietary supplement ingredient, lacking formal clinical trial approval for medical indications.
Melanotan II: Status Update
Updated notes: Melanotan II is not FDA-approved and was removed from the FDA's Category 2 compounding list in April 2026. It is currently scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before February 2027.
Updated notes: Melanotan II is not FDA-approved and was removed from the FDA's Category 2 compounding list in April 2026. It is currently scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before February 2027. Melanotan II is not FDA-approved and was removed from the FDA's Category 2 compounding list in April 2026. It is currently scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) before February 2027.
MOTS-c: Status Update
Updated notes: The FDA has identified no human clinical studies evaluating MOTS-c for its proposed indications. It was recommended by the PCAC in July 2026 for the 503A bulk list but remains an unapproved research chemical.
Updated notes: The FDA has identified no human clinical studies evaluating MOTS-c for its proposed indications. It was recommended by the PCAC in July 2026 for the 503A bulk list but remains an unapproved research chemical. The FDA has identified no human clinical studies evaluating MOTS-c for its proposed indications. It was recommended by the PCAC in July 2026 for the 503A bulk list but remains an unapproved research chemical.
MK-677: Status Update
Updated notes: MK-677 (ibutamoren) is not FDA-approved and has been the subject of FDA warning letters regarding its inclusion in unapproved products. It has reached phase 3 clinical investigation status for specific indications but lacks final regulatory approval.
Updated notes: MK-677 (ibutamoren) is not FDA-approved and has been the subject of FDA warning letters regarding its inclusion in unapproved products. It has reached phase 3 clinical investigation status for specific indications but lacks final regulatory approval. MK-677 (ibutamoren) is not FDA-approved and has been the subject of FDA warning letters regarding its inclusion in unapproved products. It has reached phase 3 clinical investigation status for specific indications but lacks final regulatory approval.
LL-37: Status Update
Clinical trial phase changed from "preclinical" to "phase_3". Updated notes: While some sources indicate phase 3 trial activity, there is no FDA-approved therapeutic product for LL-37. It remains an unapproved substance and is subject to ongoing regulatory review regarding its safety and compounding status.
Clinical trial phase changed from "preclinical" to "phase_3". Updated notes: While some sources indicate phase 3 trial activity, there is no FDA-approved therapeutic product for LL-37. It remains an unapproved substance and is subject to ongoing regulatory review regarding its safety and compounding status. While some sources indicate phase 3 trial activity, there is no FDA-approved therapeutic product for LL-37. It remains an unapproved substance and is subject to ongoing regulatory review regarding its safety and compounding status.
KPV: Status Update
Updated notes: The FDA has identified no human clinical studies for KPV. While it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A bulk drug substances list, it remains an unapproved drug.
Updated notes: The FDA has identified no human clinical studies for KPV. While it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A bulk drug substances list, it remains an unapproved drug. The FDA has identified no human clinical studies for KPV. While it was recommended by the Pharmacy Compounding Advisory Committee in July 2026 for inclusion on the 503A bulk drug substances list, it remains an unapproved drug.
KLOW: Status Update
Updated notes: KLOW is marketed as a research-only peptide stack and lacks any formal clinical trial data or FDA approval status.
Updated notes: KLOW is marketed as a research-only peptide stack and lacks any formal clinical trial data or FDA approval status. KLOW is marketed as a research-only peptide stack and lacks any formal clinical trial data or FDA approval status.
Ipamorelin / CJC-1295 No DAC: Status Update
Updated notes: This combination is not FDA-approved; while individual components have reached phase 2 trials in historical research, the stack itself has no formal clinical development program.
Updated notes: This combination is not FDA-approved; while individual components have reached phase 2 trials in historical research, the stack itself has no formal clinical development program. This combination is not FDA-approved; while individual components have reached phase 2 trials in historical research, the stack itself has no formal clinical development program.
Ipamorelin: Status Update
Updated notes: Ipamorelin reached phase 2 clinical trials for ileus but failed to meet its primary endpoint and was never approved for market by the FDA.
Updated notes: Ipamorelin reached phase 2 clinical trials for ileus but failed to meet its primary endpoint and was never approved for market by the FDA. Ipamorelin reached phase 2 clinical trials for ileus but failed to meet its primary endpoint and was never approved for market by the FDA.
IGF-1 LR3: Status Update
Clinical trial phase changed from "preclinical" to "phase_1". Updated notes: IGF-1 LR3 is classified as a research compound with no active IND applications for therapeutic use; existing human data is limited to early-stage pharmacokinetic assessments.
Clinical trial phase changed from "preclinical" to "phase_1". Updated notes: IGF-1 LR3 is classified as a research compound with no active IND applications for therapeutic use; existing human data is limited to early-stage pharmacokinetic assessments. IGF-1 LR3 is classified as a research compound with no active IND applications for therapeutic use; existing human data is limited to early-stage pharmacokinetic assessments.
Hexarelin: Status Update
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: Hexarelin has undergone limited human clinical trials, including phase 1 and 2 studies for endocrine testing, but it has never received FDA approval for therapeutic use.
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: Hexarelin has undergone limited human clinical trials, including phase 1 and 2 studies for endocrine testing, but it has never received FDA approval for therapeutic use. Hexarelin has undergone limited human clinical trials, including phase 1 and 2 studies for endocrine testing, but it has never received FDA approval for therapeutic use.
Glutathione: Status Update
Clinical trial phase changed from "approved" to "research_only". Regulatory status changed from "fda_approved" to "not_fda_approved". Updated notes: While glutathione is a naturally occurring antioxidant, no injectable glutathione product is FDA-approved for human use, and the FDA has issued warnings regarding compounded versions.
Clinical trial phase changed from "approved" to "research_only". Regulatory status changed from "fda_approved" to "not_fda_approved". Updated notes: While glutathione is a naturally occurring antioxidant, no injectable glutathione product is FDA-approved for human use, and the FDA has issued warnings regarding compounded versions. While glutathione is a naturally occurring antioxidant, no injectable glutathione product is FDA-approved for human use, and the FDA has issued warnings regarding compounded versions.
Oxytocin: Status Update
Updated notes: Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, and it is available as a prescription drug.
Updated notes: Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, and it is available as a prescription drug. Oxytocin is an FDA-approved medication used primarily for inducing labor and controlling postpartum bleeding, and it is available as a prescription drug.
GHRP-6: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GHRP-6 is not FDA-approved for any human indication and is not listed on the FDA 503A bulk drug substance list for compounding.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GHRP-6 is not FDA-approved for any human indication and is not listed on the FDA 503A bulk drug substance list for compounding. GHRP-6 is not FDA-approved for any human indication and is not listed on the FDA 503A bulk drug substance list for compounding.
GHRP-2: Status Update
Updated notes: GHRP-2 (pralmorelin) reached Phase 2 clinical trials in the U.S. for growth hormone deficiency but was never approved; it is approved as a diagnostic agent in Japan.
Updated notes: GHRP-2 (pralmorelin) reached Phase 2 clinical trials in the U.S. for growth hormone deficiency but was never approved; it is approved as a diagnostic agent in Japan. GHRP-2 (pralmorelin) reached Phase 2 clinical trials in the U.S. for growth hormone deficiency but was never approved; it is approved as a diagnostic agent in Japan.
GHK-Cu: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GHK-Cu is not FDA-approved for injectable use, though non-injectable forms appear on certain FDA compounding lists. It is widely sold as a research chemical.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GHK-Cu is not FDA-approved for injectable use, though non-injectable forms appear on certain FDA compounding lists. It is widely sold as a research chemical. GHK-Cu is not FDA-approved for injectable use, though non-injectable forms appear on certain FDA compounding lists. It is widely sold as a research chemical.
Melanotan I: Status Update
Updated notes: Melanotan I is not FDA-approved for human use. It is generally categorized as a research chemical, and there is a lack of publicly available, robust human clinical trial data supporting its use for therapeutic indications.
Updated notes: Melanotan I is not FDA-approved for human use. It is generally categorized as a research chemical, and there is a lack of publicly available, robust human clinical trial data supporting its use for therapeutic indications. Melanotan I is not FDA-approved for human use. It is generally categorized as a research chemical, and there is a lack of publicly available, robust human clinical trial data supporting its use for therapeutic indications.
Epithalon: Status Update
Updated notes: Epithalon is not FDA-approved and is primarily studied in preclinical models; no significant human clinical trial data or regulatory approval exists in the United States.
Updated notes: Epithalon is not FDA-approved and is primarily studied in preclinical models; no significant human clinical trial data or regulatory approval exists in the United States. Epithalon is not FDA-approved and is primarily studied in preclinical models; no significant human clinical trial data or regulatory approval exists in the United States.
Dihexa: Status Update
Updated notes: Dihexa was developed as a cognitive-enhancing research candidate and has only been evaluated in preclinical models; it is not approved for human use.
Updated notes: Dihexa was developed as a cognitive-enhancing research candidate and has only been evaluated in preclinical models; it is not approved for human use. Dihexa was developed as a cognitive-enhancing research candidate and has only been evaluated in preclinical models; it is not approved for human use.
DSIP: Status Update
Updated notes: Delta Sleep-Inducing Peptide (DSIP) has been the subject of historical research regarding sleep and stress, but it remains a research-only compound without FDA approval.
Updated notes: Delta Sleep-Inducing Peptide (DSIP) has been the subject of historical research regarding sleep and stress, but it remains a research-only compound without FDA approval. Delta Sleep-Inducing Peptide (DSIP) has been the subject of historical research regarding sleep and stress, but it remains a research-only compound without FDA approval.
Kisspeptin-10: Status Update
Updated notes: Kisspeptin-10 is currently listed in the FDA's Category 2, indicating it is considered to pose a significant safety risk for compounding. There is no FDA-approved product containing this peptide.
Updated notes: Kisspeptin-10 is currently listed in the FDA's Category 2, indicating it is considered to pose a significant safety risk for compounding. There is no FDA-approved product containing this peptide. Kisspeptin-10 is currently listed in the FDA's Category 2, indicating it is considered to pose a significant safety risk for compounding. There is no FDA-approved product containing this peptide.
Cartalax: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Cartalax is a synthetic peptide bioregulator primarily studied in preclinical research for cartilage and joint health; it lacks FDA approval for clinical use.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Cartalax is a synthetic peptide bioregulator primarily studied in preclinical research for cartilage and joint health; it lacks FDA approval for clinical use. Cartalax is a synthetic peptide bioregulator primarily studied in preclinical research for cartilage and joint health; it lacks FDA approval for clinical use.
Cagrilintide: Status Update
Regulatory status changed from "not_fda_approved" to "phase_3_trial". Updated notes: Cagrilintide is currently in phase 3 clinical trials, often studied in combination with semaglutide (CagriSema) for the treatment of obesity and type 2 diabetes.
Regulatory status changed from "not_fda_approved" to "phase_3_trial". Updated notes: Cagrilintide is currently in phase 3 clinical trials, often studied in combination with semaglutide (CagriSema) for the treatment of obesity and type 2 diabetes. Cagrilintide is currently in phase 3 clinical trials, often studied in combination with semaglutide (CagriSema) for the treatment of obesity and type 2 diabetes.
CJC-1295 No DAC: Status Update
Updated notes: CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in research settings and is not approved by the FDA for human use.
Updated notes: CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in research settings and is not approved by the FDA for human use. CJC-1295 (without Drug Affinity Complex) is a growth hormone-releasing hormone analog primarily used in research settings and is not approved by the FDA for human use.
CJC-1295: Status Update
Updated notes: CJC-1295 reached phase 2 clinical trials (NCT00267527) but is not FDA-approved, and the FDA has identified potential safety risks regarding its use in compounding.
Updated notes: CJC-1295 reached phase 2 clinical trials (NCT00267527) but is not FDA-approved, and the FDA has identified potential safety risks regarding its use in compounding. CJC-1295 reached phase 2 clinical trials (NCT00267527) but is not FDA-approved, and the FDA has identified potential safety risks regarding its use in compounding.
BPC-157: Status Update
Updated notes: BPC-157 is not FDA-approved for human use, and its nomination for inclusion on the 503A bulk drug substances list has been withdrawn.
Updated notes: BPC-157 is not FDA-approved for human use, and its nomination for inclusion on the 503A bulk drug substances list has been withdrawn. BPC-157 is not FDA-approved for human use, and its nomination for inclusion on the 503A bulk drug substances list has been withdrawn.
ARA-290: Status Update
Updated notes: ARA-290 (cibinetide) has reached phase 2 clinical trials but remains not FDA-approved and is currently categorized as a research-only compound.
Updated notes: ARA-290 (cibinetide) has reached phase 2 clinical trials but remains not FDA-approved and is currently categorized as a research-only compound. ARA-290 (cibinetide) has reached phase 2 clinical trials but remains not FDA-approved and is currently categorized as a research-only compound.
AOD-9604: Status Update
Updated notes: AOD-9604 completed multiple human trials, including a phase 2b study, but failed to achieve statistical significance and is not FDA-approved.
Updated notes: AOD-9604 completed multiple human trials, including a phase 2b study, but failed to achieve statistical significance and is not FDA-approved. AOD-9604 completed multiple human trials, including a phase 2b study, but failed to achieve statistical significance and is not FDA-approved.
AICAR: Status Update
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: AICAR has undergone phase 2 pilot studies but is not an FDA-approved product and has no established medical use in humans.
Clinical trial phase changed from "preclinical" to "phase_2". Updated notes: AICAR has undergone phase 2 pilot studies but is not an FDA-approved product and has no established medical use in humans. AICAR has undergone phase 2 pilot studies but is not an FDA-approved product and has no established medical use in humans.
5-Amino-1MQ: Status Update
Updated notes: There are no registered human clinical trials for 5-Amino-1MQ, and it is not approved by the FDA for any medical indication.
Updated notes: There are no registered human clinical trials for 5-Amino-1MQ, and it is not approved by the FDA for any medical indication. There are no registered human clinical trials for 5-Amino-1MQ, and it is not approved by the FDA for any medical indication.
GLOW: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GLOW is a market-labeled blend of GHK-Cu, BPC-157, and TB-500 with no human clinical trials; none of its individual components are FDA-approved for this use.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: GLOW is a market-labeled blend of GHK-Cu, BPC-157, and TB-500 with no human clinical trials; none of its individual components are FDA-approved for this use. GLOW is a market-labeled blend of GHK-Cu, BPC-157, and TB-500 with no human clinical trials; none of its individual components are FDA-approved for this use.
Vilon: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vilon is an investigational peptide with no formal human clinical trials registered and no FDA approval for any therapeutic use.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vilon is an investigational peptide with no formal human clinical trials registered and no FDA approval for any therapeutic use. Vilon is an investigational peptide with no formal human clinical trials registered and no FDA approval for any therapeutic use.
Vesugen: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vesugen is an investigational peptide bioregulator with no registered clinical trials or FDA/EMA approval.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Vesugen is an investigational peptide bioregulator with no registered clinical trials or FDA/EMA approval. Vesugen is an investigational peptide bioregulator with no registered clinical trials or FDA/EMA approval.
VIP: Status Update
Updated notes: Vasoactive Intestinal Peptide (VIP) is currently in the research stage for various therapeutic applications and lacks FDA approval for human use.
Updated notes: Vasoactive Intestinal Peptide (VIP) is currently in the research stage for various therapeutic applications and lacks FDA approval for human use. Vasoactive Intestinal Peptide (VIP) is currently in the research stage for various therapeutic applications and lacks FDA approval for human use.
Follistatin 344: Status Update
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: Follistatin-344 is not FDA-approved and is prohibited by WADA as a myostatin inhibitor. While gene therapy versions remain investigational, the injectable peptide form has no completed clinical trials.
Clinical trial phase changed from "phase_1" to "preclinical". Updated notes: Follistatin-344 is not FDA-approved and is prohibited by WADA as a myostatin inhibitor. While gene therapy versions remain investigational, the injectable peptide form has no completed clinical trials. Follistatin-344 is not FDA-approved and is prohibited by WADA as a myostatin inhibitor. While gene therapy versions remain investigational, the injectable peptide form has no completed clinical trials.
Cerebrolysin: Status Update
Updated notes: Cerebrolysin is approved for use in several countries outside the United States for stroke and dementia, but it is not FDA-approved for any indication.
Updated notes: Cerebrolysin is approved for use in several countries outside the United States for stroke and dementia, but it is not FDA-approved for any indication. Cerebrolysin is approved for use in several countries outside the United States for stroke and dementia, but it is not FDA-approved for any indication.
Tirzepatide: Status Update
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea.
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Tirzepatide is FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea.
Thymosin Beta-4 Full Fragment: Status Update
Updated notes: The full-length protein has undergone Phase 3 trials for neurotrophic keratopathy, but it remains not FDA-approved for any indication.
Updated notes: The full-length protein has undergone Phase 3 trials for neurotrophic keratopathy, but it remains not FDA-approved for any indication. The full-length protein has undergone Phase 3 trials for neurotrophic keratopathy, but it remains not FDA-approved for any indication.
Thymosin Beta-4 (Fragment): Status Update
Updated notes: Often referred to as TB-500, this fragment lacks human clinical trial data and is primarily supported by preclinical research.
Updated notes: Often referred to as TB-500, this fragment lacks human clinical trial data and is primarily supported by preclinical research. Often referred to as TB-500, this fragment lacks human clinical trial data and is primarily supported by preclinical research.
Thymosin Alpha-1: Status Update
Clinical trial phase changed from "phase_3" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: Thymosin Alpha-1 is not FDA-approved in the United States, despite being approved as a pharmaceutical in over 35 other countries.
Clinical trial phase changed from "phase_3" to "research_only". Regulatory status changed from "approved_international_only" to "not_fda_approved". Updated notes: Thymosin Alpha-1 is not FDA-approved in the United States, despite being approved as a pharmaceutical in over 35 other countries. Thymosin Alpha-1 is not FDA-approved in the United States, despite being approved as a pharmaceutical in over 35 other countries.
Tesamorelin: Status Update
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of HIV-associated lipodystrophy, following successful Phase 3 clinical trials.
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of HIV-associated lipodystrophy, following successful Phase 3 clinical trials. Tesamorelin is FDA-approved under the brand name EGRIFTA (and its variants) for the treatment of HIV-associated lipodystrophy, following successful Phase 3 clinical trials.
TB-500: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: TB-500 is not FDA-approved and is considered an investigational compound, though it was recommended for the 503A bulks list by the PCAC in July 2026.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: TB-500 is not FDA-approved and is considered an investigational compound, though it was recommended for the 503A bulks list by the PCAC in July 2026. TB-500 is not FDA-approved and is considered an investigational compound, though it was recommended for the 503A bulks list by the PCAC in July 2026.
Sermorelin: Status Update
Clinical trial phase changed from "approved" to "research_only". Updated notes: Sermorelin is not FDA-approved as a finished drug, though its API remains on Category 1 of the 503A bulk drug substances list for compounding.
Clinical trial phase changed from "approved" to "research_only". Updated notes: Sermorelin is not FDA-approved as a finished drug, though its API remains on Category 1 of the 503A bulk drug substances list for compounding. Sermorelin is not FDA-approved as a finished drug, though its API remains on Category 1 of the 503A bulk drug substances list for compounding.
Semax: Status Update
Clinical trial phase changed from "phase_3" to "research_only". Updated notes: Semax is not FDA-approved; while the Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in July 2026, this is an advisory recommendation and not drug approval.
Clinical trial phase changed from "phase_3" to "research_only". Updated notes: Semax is not FDA-approved; while the Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in July 2026, this is an advisory recommendation and not drug approval. Semax is not FDA-approved; while the Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in July 2026, this is an advisory recommendation and not drug approval.
Semaglutide: Status Update
Updated notes: Semaglutide is FDA-approved under brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing approvals for new dosage forms as of 2026.
Updated notes: Semaglutide is FDA-approved under brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing approvals for new dosage forms as of 2026. Semaglutide is FDA-approved under brand names Ozempic (2017) for type 2 diabetes and Wegovy (2021) for obesity, with ongoing approvals for new dosage forms as of 2026.
Selank: Status Update
Updated notes: Selank is a synthetic peptide developed in Russia for anxiety and cognitive support; it is not FDA-approved and lacks a formal clinical development program in the United States.
Updated notes: Selank is a synthetic peptide developed in Russia for anxiety and cognitive support; it is not FDA-approved and lacks a formal clinical development program in the United States. Selank is a synthetic peptide developed in Russia for anxiety and cognitive support; it is not FDA-approved and lacks a formal clinical development program in the United States.
SS-31: Status Update
Updated notes: Elamipretide (SS-31) received FDA approval in 2025 under the brand name Forzinity (NDA 215244) for the treatment of Barth syndrome.
Updated notes: Elamipretide (SS-31) received FDA approval in 2025 under the brand name Forzinity (NDA 215244) for the treatment of Barth syndrome. Elamipretide (SS-31) received FDA approval in 2025 under the brand name Forzinity (NDA 215244) for the treatment of Barth syndrome.
SLU-PP-332: Status Update
Updated notes: SLU-PP-332 is a research-use small molecule with no active IND application or human clinical trials; all evidence is currently limited to preclinical animal and in-vitro studies.
Updated notes: SLU-PP-332 is a research-use small molecule with no active IND application or human clinical trials; all evidence is currently limited to preclinical animal and in-vitro studies. SLU-PP-332 is a research-use small molecule with no active IND application or human clinical trials; all evidence is currently limited to preclinical animal and in-vitro studies.
Retatrutide: Status Update
Updated notes: Retatrutide is an investigational triple agonist currently in Phase 3 clinical trials (TRIUMPH program) for obesity and metabolic conditions; it has not received FDA approval.
Updated notes: Retatrutide is an investigational triple agonist currently in Phase 3 clinical trials (TRIUMPH program) for obesity and metabolic conditions; it has not received FDA approval. Retatrutide is an investigational triple agonist currently in Phase 3 clinical trials (TRIUMPH program) for obesity and metabolic conditions; it has not received FDA approval.
Pinealon: Status Update
Updated notes: Pinealon is a synthetic peptide primarily studied in Russia; it has no FDA approval and is not currently undergoing active clinical trials in the United States.
Updated notes: Pinealon is a synthetic peptide primarily studied in Russia; it has no FDA approval and is not currently undergoing active clinical trials in the United States. Pinealon is a synthetic peptide primarily studied in Russia; it has no FDA approval and is not currently undergoing active clinical trials in the United States.
PNC-27: Status Update
Updated notes: PNC-27 is not FDA-approved and remains in the preclinical research stage, with no formal clinical trial status or regulatory authorization for human use.
Updated notes: PNC-27 is not FDA-approved and remains in the preclinical research stage, with no formal clinical trial status or regulatory authorization for human use. PNC-27 is not FDA-approved and remains in the preclinical research stage, with no formal clinical trial status or regulatory authorization for human use.
PEG-MGF: Status Update
Updated notes: PEG-MGF is not FDA-approved and has no active commercial sponsor pursuing a clinical trial pathway; it is widely classified as a research-use-only compound.
Updated notes: PEG-MGF is not FDA-approved and has no active commercial sponsor pursuing a clinical trial pathway; it is widely classified as a research-use-only compound. PEG-MGF is not FDA-approved and has no active commercial sponsor pursuing a clinical trial pathway; it is widely classified as a research-use-only compound.
Vilon: Status Update
Updated notes: Vilon (a dipeptide) is primarily utilized in research and is not FDA-approved for any medical indication.
Updated notes: Vilon (a dipeptide) is primarily utilized in research and is not FDA-approved for any medical indication. Vilon (a dipeptide) is primarily utilized in research and is not FDA-approved for any medical indication.
Vesugen: Status Update
Updated notes: Vesugen is a synthetic peptide primarily studied in international research contexts and lacks FDA approval for human use.
Updated notes: Vesugen is a synthetic peptide primarily studied in international research contexts and lacks FDA approval for human use. Vesugen is a synthetic peptide primarily studied in international research contexts and lacks FDA approval for human use.
VIP: Status Update
Clinical trial phase changed from "phase_2" to "research_only". Updated notes: Vasoactive Intestinal Peptide (VIP) is primarily used in research settings and is not currently FDA-approved as a therapeutic drug.
Clinical trial phase changed from "phase_2" to "research_only". Updated notes: Vasoactive Intestinal Peptide (VIP) is primarily used in research settings and is not currently FDA-approved as a therapeutic drug. Vasoactive Intestinal Peptide (VIP) is primarily used in research settings and is not currently FDA-approved as a therapeutic drug.
Tirzepatide: Status Update
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound for the treatment of type 2 diabetes and chronic weight management.
Updated notes: Tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound for the treatment of type 2 diabetes and chronic weight management. Tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound for the treatment of type 2 diabetes and chronic weight management.
Thymosin Beta-4 Full Fragment: Status Update
Updated notes: The full-length protein has reached Phase 3 clinical trials for indications such as neurotrophic keratopathy and dry eye disease but remains not FDA-approved.
Updated notes: The full-length protein has reached Phase 3 clinical trials for indications such as neurotrophic keratopathy and dry eye disease but remains not FDA-approved. The full-length protein has reached Phase 3 clinical trials for indications such as neurotrophic keratopathy and dry eye disease but remains not FDA-approved.
Thymosin Beta-4 (Fragment): Status Update
Updated notes: Often marketed as TB-500, this fragment lacks human clinical trial data and is not FDA-approved for any use.
Updated notes: Often marketed as TB-500, this fragment lacks human clinical trial data and is not FDA-approved for any use. Often marketed as TB-500, this fragment lacks human clinical trial data and is not FDA-approved for any use.
Thymosin Alpha-1: Status Update
Updated notes: Thymosin Alpha-1 is approved as a pharmaceutical in over 35 countries (e.g., as Zadaxin) but has not received FDA approval in the United States.
Updated notes: Thymosin Alpha-1 is approved as a pharmaceutical in over 35 countries (e.g., as Zadaxin) but has not received FDA approval in the United States. Thymosin Alpha-1 is approved as a pharmaceutical in over 35 countries (e.g., as Zadaxin) but has not received FDA approval in the United States.
Tesamorelin: Status Update
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA for the treatment of HIV-associated lipodystrophy.
Updated notes: Tesamorelin is FDA-approved under the brand name EGRIFTA for the treatment of HIV-associated lipodystrophy. Tesamorelin is FDA-approved under the brand name EGRIFTA for the treatment of HIV-associated lipodystrophy.
TB-500: Status Update
Updated notes: TB-500 is considered an investigational compound with no FDA approval for human use; it is widely categorized as research-only.
Updated notes: TB-500 is considered an investigational compound with no FDA approval for human use; it is widely categorized as research-only. TB-500 is considered an investigational compound with no FDA approval for human use; it is widely categorized as research-only.
Sermorelin: Status Update
Clinical trial phase changed from "phase_3" to "approved". Updated notes: Sermorelin is not currently FDA-approved as a drug product, but its API is listed on the FDA's Category 1 list, allowing it to be legally compounded by 503A pharmacies.
Clinical trial phase changed from "phase_3" to "approved". Updated notes: Sermorelin is not currently FDA-approved as a drug product, but its API is listed on the FDA's Category 1 list, allowing it to be legally compounded by 503A pharmacies. Sermorelin is not currently FDA-approved as a drug product, but its API is listed on the FDA's Category 1 list, allowing it to be legally compounded by 503A pharmacies.
Semax: Status Update
Updated notes: Semax is approved for use in Russia but lacks FDA approval; an FDA advisory committee recommended its inclusion on the 503A compounding list in July 2026, though rulemaking is pending.
Updated notes: Semax is approved for use in Russia but lacks FDA approval; an FDA advisory committee recommended its inclusion on the 503A compounding list in July 2026, though rulemaking is pending. Semax is approved for use in Russia but lacks FDA approval; an FDA advisory committee recommended its inclusion on the 503A compounding list in July 2026, though rulemaking is pending.
Semaglutide: Status Update
Updated notes: Semaglutide is FDA-approved under brand names Ozempic and Wegovy for type 2 diabetes and obesity, with ongoing clinical trials for additional indications like MASH.
Updated notes: Semaglutide is FDA-approved under brand names Ozempic and Wegovy for type 2 diabetes and obesity, with ongoing clinical trials for additional indications like MASH. Semaglutide is FDA-approved under brand names Ozempic and Wegovy for type 2 diabetes and obesity, with ongoing clinical trials for additional indications like MASH.
Selank: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Selank is a synthetic peptide developed internationally but is not FDA-approved for any medical use in the United States and remains a research-only compound.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Selank is a synthetic peptide developed internationally but is not FDA-approved for any medical use in the United States and remains a research-only compound. Selank is a synthetic peptide developed internationally but is not FDA-approved for any medical use in the United States and remains a research-only compound.
SS-31: Status Update
Updated notes: Elamipretide (SS-31) received FDA approval under the brand name Forzinity (NDA 215244) in September 2025.
Updated notes: Elamipretide (SS-31) received FDA approval under the brand name Forzinity (NDA 215244) in September 2025. Elamipretide (SS-31) received FDA approval under the brand name Forzinity (NDA 215244) in September 2025.
SLU-PP-332: Status Update
Updated notes: SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no registered human clinical trials.
Updated notes: SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no registered human clinical trials. SLU-PP-332 is a research tool compound studied only in preclinical models; it has no IND application on file and no registered human clinical trials.
Retatrutide: Status Update
Updated notes: Retatrutide is an investigational triple agonist currently undergoing Phase 3 clinical trials (TRIUMPH program) for obesity and related metabolic conditions; it is not yet FDA-approved.
Updated notes: Retatrutide is an investigational triple agonist currently undergoing Phase 3 clinical trials (TRIUMPH program) for obesity and related metabolic conditions; it is not yet FDA-approved. Retatrutide is an investigational triple agonist currently undergoing Phase 3 clinical trials (TRIUMPH program) for obesity and related metabolic conditions; it is not yet FDA-approved.
Pinealon: Status Update
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no active clinical development program in the United States.
Clinical trial phase changed from "preclinical" to "research_only". Updated notes: Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no active clinical development program in the United States. Pinealon is a synthetic peptide primarily studied in international research settings; it lacks FDA approval and has no active clinical development program in the United States.
PT-141: Status Update
Updated notes: Bremelanotide is FDA-approved under the brand name Vyleesi (NDA 210557) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Updated notes: Bremelanotide is FDA-approved under the brand name Vyleesi (NDA 210557) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. Bremelanotide is FDA-approved under the brand name Vyleesi (NDA 210557) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
PEG-MGF: Status Update
Updated notes: PEG-MGF is not FDA-approved and is classified as a research-only substance. It was removed from the FDA's Category 2 list in April 2026 and remains subject to further safety evaluation.
Updated notes: PEG-MGF is not FDA-approved and is classified as a research-only substance. It was removed from the FDA's Category 2 list in April 2026 and remains subject to further safety evaluation. PEG-MGF is not FDA-approved and is classified as a research-only substance. It was removed from the FDA's Category 2 list in April 2026 and remains subject to further safety evaluation.
Oxytocin: Status Update
Updated notes: Oxytocin is an FDA-approved medication used primarily to induce labor, control postpartum bleeding, and facilitate breastfeeding.
Updated notes: Oxytocin is an FDA-approved medication used primarily to induce labor, control postpartum bleeding, and facilitate breastfeeding. Oxytocin is an FDA-approved medication used primarily to induce labor, control postpartum bleeding, and facilitate breastfeeding.
Ovagen: Status Update
Updated notes: Ovagen is a research-grade peptide with no established clinical trial history or FDA approval for human use.
Updated notes: Ovagen is a research-grade peptide with no established clinical trial history or FDA approval for human use. Ovagen is a research-grade peptide with no established clinical trial history or FDA approval for human use.
NAD+: Status Update
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Updated notes: NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication. NAD+ is currently being investigated in various clinical trials for conditions such as metabolic disorders and aging, but it has not received FDA approval for any therapeutic indication.
Melanotan II: Status Update
Updated notes: Melanotan II is not FDA-approved and was removed from the FDA's Category 2 bulk drug substances list in April 2026. It is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected before February 2027.
Updated notes: Melanotan II is not FDA-approved and was removed from the FDA's Category 2 bulk drug substances list in April 2026. It is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected before February 2027. Melanotan II is not FDA-approved and was removed from the FDA's Category 2 bulk drug substances list in April 2026. It is currently under review by the Pharmacy Compounding Advisory Committee (PCAC) with a decision expected before February 2027.
Melanotan I: Status Update
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Melanotan I is not FDA-approved for human use and remains classified as a research-only substance.
Clinical trial phase changed from "research_only" to "preclinical". Updated notes: Melanotan I is not FDA-approved for human use and remains classified as a research-only substance. Melanotan I is not FDA-approved for human use and remains classified as a research-only substance.
MOTS-c: Status Update
Updated notes: The FDA has identified no human clinical studies for MOTS-c, and it is not an ingredient in any approved drug product.
Updated notes: The FDA has identified no human clinical studies for MOTS-c, and it is not an ingredient in any approved drug product. The FDA has identified no human clinical studies for MOTS-c, and it is not an ingredient in any approved drug product.
MK-677: Status Update
Updated notes: MK-677 (ibutamoren) has reached phase 3 clinical trials but remains a non-FDA-approved substance for human use.
Updated notes: MK-677 (ibutamoren) has reached phase 3 clinical trials but remains a non-FDA-approved substance for human use. MK-677 (ibutamoren) has reached phase 3 clinical trials but remains a non-FDA-approved substance for human use.
LL-37: Status Update
Clinical trial phase changed from "phase_3" to "preclinical". Updated notes: While LL-37 has been studied in laboratory and human contexts, there is no FDA-approved therapeutic product, and it is not authorized for compounding.
Clinical trial phase changed from "phase_3" to "preclinical". Updated notes: While LL-37 has been studied in laboratory and human contexts, there is no FDA-approved therapeutic product, and it is not authorized for compounding. While LL-37 has been studied in laboratory and human contexts, there is no FDA-approved therapeutic product, and it is not authorized for compounding.
Kisspeptin-10: Status Update
Updated notes: Kisspeptin-10 is a research peptide with no FDA-approved products; human research is limited to small, early-stage investigational studies.
Updated notes: Kisspeptin-10 is a research peptide with no FDA-approved products; human research is limited to small, early-stage investigational studies. Kisspeptin-10 is a research peptide with no FDA-approved products; human research is limited to small, early-stage investigational studies.
KPV: Status Update
Updated notes: The FDA has identified no human clinical studies for KPV, and it remains an investigational substance not approved for human use.
Updated notes: The FDA has identified no human clinical studies for KPV, and it remains an investigational substance not approved for human use. The FDA has identified no human clinical studies for KPV, and it remains an investigational substance not approved for human use.
KLOW: Status Update
Updated notes: KLOW is a research-only compound with no clinical trial data or FDA approval status available.
Updated notes: KLOW is a research-only compound with no clinical trial data or FDA approval status available. KLOW is a research-only compound with no clinical trial data or FDA approval status available.
Ipamorelin / CJC-1295 No DAC: Status Update
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: This combination is not FDA-approved; individual components like CJC-1295 had clinical development halted at the Phase 2 stage.
Clinical trial phase changed from "research_only" to "phase_2". Updated notes: This combination is not FDA-approved; individual components like CJC-1295 had clinical development halted at the Phase 2 stage. This combination is not FDA-approved; individual components like CJC-1295 had clinical development halted at the Phase 2 stage.
Ipamorelin: Status Update
Updated notes: Ipamorelin has not reached market as a drug and has not completed the Phase 3 trials required for FDA approval.
Updated notes: Ipamorelin has not reached market as a drug and has not completed the Phase 3 trials required for FDA approval. Ipamorelin has not reached market as a drug and has not completed the Phase 3 trials required for FDA approval.
IGF-1 LR3: Status Update
Updated notes: IGF-1 LR3 is classified as a research chemical with no FDA approval for any indication; it is distinct from the FDA-approved drug mecasermin.
Updated notes: IGF-1 LR3 is classified as a research chemical with no FDA approval for any indication; it is distinct from the FDA-approved drug mecasermin. IGF-1 LR3 is classified as a research chemical with no FDA approval for any indication; it is distinct from the FDA-approved drug mecasermin.
Hexarelin: Status Update
Updated notes: Hexarelin is a research-only peptide that has not been approved for human therapeutic use and is prohibited in sport by WADA.
Updated notes: Hexarelin is a research-only peptide that has not been approved for human therapeutic use and is prohibited in sport by WADA. Hexarelin is a research-only peptide that has not been approved for human therapeutic use and is prohibited in sport by WADA.